Cover Image
市场调查报告书

肾上腺皮质癌症:开发中产品分析

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品编码 213047
出版日期 内容信息 英文 111 Pages
订单完成后即时交付
价格
Back to Top
肾上腺皮质癌症:开发中产品分析 Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2018
出版日期: 2018年04月17日 内容信息: 英文 111 Pages
简介

肾上腺皮质癌是肾上腺皮质肿瘤增生的罕见疾病。发病因子有姓别、影响肾上腺的遗传疾病、高龄、吸烟等,症状有高血糖、高血压、下肢肌肉无力、胸部及腹部过度脂肪堆积、脸部及体毛增加、声音变低等。

本报告提供全球各国治疗肾上腺皮质癌症所用的开发中产品之开发情形相关分析,提供开发中产品的最新趋势,及临床实验的各阶段产品一览,主要企业简介,主要药物概要(产品概要,功能机制,研究开发(R&D)的发展情形),最新的产业趋势等调查,并将结果概述为以下内容。

目录

简介

  • 分析范围

肾上腺皮质癌症概要

治疗药的开发

  • 肾上腺皮质癌症开发中产品:概要
  • 各企业的治疗药
  • 企业开发中的产品

肾上腺皮质癌症:治疗药的评估

  • 标的别
  • 各作用机制
  • 各给药途径
  • 分子各类型

肾上腺皮质癌症开发治疗药的企业

  • ArQule Inc
  • EnGeneIC Ltd
  • Exelixis Inc
  • Merck KGaA
  • Millendo Therapeutics Inc
  • Orphagen Pharmaceuticals Inc

肾上腺皮质癌症:治疗药简介

肾上腺皮质癌症治疗药:开发暂停中的计划

肾上腺皮质癌症治疗药:开发中止的产品

肾上腺皮质癌症相关产品的开发的里程碑

  • 值得注意的最新趋势·新闻稿

附录

图表一览

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC10360IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2018, provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline landscape.

Adrenal cortex cancer (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. Predisposing factors include female, hereditary disease that affects the adrenal glands, age and smoking. Symptoms include high blood sugar and pressure, muscle weakness in the legs, excessive weight gain in chest and abdomen, early signs of puberty in children, increased facial and body hair, particularly in females and deepened voice in females.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • ArQule Inc
  • Bristol-Myers Squibb Co
  • Exelixis Inc
  • Infinity Pharmaceuticals Inc
  • Merck KGaA
  • Millendo Therapeutics Inc
  • Orphagen Pharmaceuticals Inc
  • Trovagene Inc
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Drug Profiles
  • 8H-9 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ABBV-176 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • avelumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cabozantinib s-malate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • derazantinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IPI-549 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ipilimumab + nivolumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody Conjugate to Target B7-H3 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nevanimibe hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PCM-075 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize SF-1 for Cushing's Syndrome, Endometriosis and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Product Development Milestones
  • Featured News & Press Releases
  • Jan 08, 2018: Infinity Provides Update on IPI-549 Phase I/Ib Study, 2018 Goals and Financial Guidance
  • Nov 10, 2017: Infinity Pharmaceuticals Reports IPI-549 Clinical and Translational Data from Completed Monotherapy Dose-Escalation Component of Phase 1/1b Clinical Study in Patients with Advanced Solid Tumors at SITC Annual Meeting
  • Mar 28, 2017: Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Endogenous Cushing's Syndrome
  • Mar 18, 2016: Millendo Therapeutics Announces Publication of Preclinical Data for ATR-101 and Data Presentations at ENDO 2016
  • Mar 03, 2015: Atterocor Announces Data Presentations at ENDO 2015
  • Dec 11, 2014: Atterocor Expands Phase 1 Trial of ATR-101 to Additional Leading Adrenal Cancer Centers
  • Oct 15, 2013: Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by AbbVie Inc, H1 2018
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by ArQule Inc, H1 2018
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Bristol-Myers Squibb Co, H1 2018
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Exelixis Inc, H1 2018
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Infinity Pharmaceuticals Inc, H1 2018
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Merck KGaA, H1 2018
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Millendo Therapeutics Inc, H1 2018
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Orphagen Pharmaceuticals Inc, H1 2018
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Trovagene Inc, H1 2018
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects, H1 2018
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top